Farther Finance Advisors LLC Buys 1,440 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Farther Finance Advisors LLC increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 226.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 2,077 shares of the company's stock after purchasing an additional 1,440 shares during the quarter. Farther Finance Advisors LLC's holdings in IDEXX Laboratories were worth $869,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Geode Capital Management LLC increased its position in shares of IDEXX Laboratories by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock valued at $948,279,000 after purchasing an additional 37,734 shares during the last quarter. Bamco Inc. NY boosted its holdings in IDEXX Laboratories by 4.3% during the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock valued at $829,163,000 after acquiring an additional 82,264 shares during the period. Invesco Ltd. boosted its holdings in IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock valued at $479,999,000 after acquiring an additional 74,324 shares during the period. Norges Bank purchased a new position in IDEXX Laboratories during the 4th quarter valued at $412,258,000. Finally, GAMMA Investing LLC boosted its holdings in IDEXX Laboratories by 59,810.7% during the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock valued at $3,856,950,000 after acquiring an additional 916,898 shares during the period. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Trading Down 0.8%

Shares of NASDAQ IDXX opened at $522.70 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The stock has a market capitalization of $42.04 billion, a P/E ratio of 48.99, a price-to-earnings-growth ratio of 3.41 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.73. The business has a fifty day moving average price of $473.11 and a 200 day moving average price of $444.30.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same period in the prior year, the business posted $2.71 EPS. The firm's quarterly revenue was up 3.6% on a year-over-year basis. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Leerink Partners boosted their price objective on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday. Stifel Nicolaus boosted their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Morgan Stanley boosted their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $546.00.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,046 shares of the firm's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $513.74, for a total transaction of $537,372.04. Following the completion of the sale, the director now owns 262 shares of the company's stock, valued at $134,599.88. This trade represents a 79.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.98% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.